629-09-4

Basic information

• Product Name: 1,6-DIIODOHEXANE
• Synonyms: 1,6-diiodo-hexan;Hexane,1,6-diiodo-;1,6-DIIODOHEXANE;HEXAMETHYLENE DIIODIDE;HEXAMETHYLENEIODIDE;1,6-Diiodohexane,98+%;1,6-Diiodohexane (stabilized with Copper chip);1,6-DIIODOHEXANE, STABILIZED, 97%
• CAS NO: 629-09-4
• Molecular Formula: C₆H₁₂I₂
• Molecular Weight: 337.97
• EINECS: 211-073-5
• Product Categories: Iodine Compounds;Alkyl;Halogenated Hydrocarbons;Organic Building Blocks
• Mol File: 629-09-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 9-10 °C
• Boiling Point: 141-142 °C (10 mmHg)
• Flash Point: >110°C
• Appearance: Clear, colorless to pale yellow liquid.
• Density: 2.052
• Vapor Pressure: 0.00582mmHg at 25°C
• Refractive Index: 1.5852-1.5872
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Water Solubility: Immiscible with water.
• Sensitive: Light Sensitive
• BRN: 1280128
• CAS DataBase Reference: 1,6-DIIODOHEXANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-DIIODOHEXANE(629-09-4)
• EPA Substance Registry System: 1,6-DIIODOHEXANE(629-09-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• RIDADR: 2810
• WGK Germany: 3
• RTECS: MO1700000
• TSCA: Yes
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 629-09-4(Hazardous Substances Data)

Usage

Chemical Properties

clear light yellow liquid

Uses

1,6-Diiodohexane is used as a precursor in the preparation of cationic tissue plasminogen activator (t-PA)-containing polyurethane surfaces. It is also used as a solvent additive and in potential power conversion efficiency of polymer or fullerene bulk heterojunction solar cells. Further, it is employed in the preparation of 3-(iodohexyl)-1-(3-(triethoxysilyl)propylcarbamoyl)-1H-benzo[d]imidazol-3-ium iodide and 2,4-dihydroxybenzophenone.

InChI:InChI=1/C6H12I2/c7-5-3-1-2-4-6-8/h1-6H2

Upstream product

• 592-90-5 oxepane 
• 128429-21-0 1,6-diethoxy-hexane 
• 10034-85-2 hydrogen iodide 
• 629-03-8 1 ,6-dibromohexane 
• 629-11-8 1,6-hexanediol 
• 62116-23-8 1,6-dibromohexa-2,4-diene 
• 2235-12-3 1,3,5-hexatriene 
• 2163-00-0 1,6-dichlorohexane 

Downstream Products

• 6222-17-9 1,6-diacetoxyhexane 
• 22915-73-7 hexane-1,6-diyl dibenzoate 
• 629-40-3 octanedinitrile 
• 4753-80-4 thiepane 
• 629-11-8 1,6-hexanediol 
• 4286-47-9 1,6-dinitrohexane 
• 29747-19-1 7-hexadecynyl iodide 
• 13287-11-1 2,11-dimethyl-dodeca-1,11-diene 
• 79-90-3 triclobisonium chloride 
• 13083-96-0 1,6-bis(trimethylsilyl)hexane 
• 138942-65-1 C₉₂H₇₀N₁₀⁽²⁺⁾*2I^(1-) 
• 138942-68-4 C₁₄₀H₁₁₀N₁₆⁽⁴⁺⁾*4I^(1-) 
• 138942-69-5 C₉₂H₇₀N₁₀⁽²⁺⁾*2HO^(1-) 
• 134486-63-8 3-(8-Methylene-dodecyl)-cyclohexanone 

Relevant articles and documents

Probing the Existence of a Metastable Binding Site at the β2-Adrenergic Receptor with Homobivalent Bitopic Ligands

Herein, we report the development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit. Previous molecular dynamics studies on ligand binding to the β2-adrenergic receptor (β2AR) suggested that ligands pause at transient, less-conserved MBSs. We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic ligands linking two identical pharmacophores. Such ligands were designed based on docking of the antagonist (S)-alprenolol into the OBS and an MBS and synthesized. Pharmacological characterization revealed ligands with similar potency and affinity, slightly increased β2/β1AR-selectivity, and/or substantially slower β2AR off-rates compared to (S)-alprenolol. Truncated bitopic ligands suggested the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the β2AR, while the linkers alone decreased the potency of the orthosteric fragment. Altogether, the study underlines the potential of targeting MBSs for improving the pharmacological profiles of ligands.

Applications of surfactant-modified clays to synthetic organic chemistry

Two triphase catalysts (SLL) have been developed for organic phase-aqueous phase reactions catalyzed by suitable modified clay (solid phase). These triphase catalysts have been applied to nucleophilic displacement on activated (benzylic) as well as unactivated organic halides and provide a convenient and effective method of preparation of the corresponding products. Other useful transformations to, which these triphase catalysts have been successfully applied are the synthesis of 9,9-dichloro bicyclo[6.1.0]nonane, O-alkylation and C-alkylation of β-naphthol.

Pharmaceutically active compounds

Compounds of the formula pharmaceutically acceptable acid addition, basic addition salts or quaternary amine salts thereof, wherein Z is phenyl, substituted phenyl, wherein the substituents are independently one or more of halogen, lower alkylthio, loweralkylsulfonyl, lower alkoxy, oxazol-2-yl; imidazo-1-yl; lower alkyl substituted imidazo-1-yl; or tert-butyl; X is a bond, STR1 Q is lower alkane-diyl or 5, 6, or 7 carbon atoms optionally substituted by --OH; loweralkylnediyl of 6-8 carbon atoms; methylcyclohexylmethyl; tetrahydrofurandiyl; or (C1 -C2) lower alkane-diyl tetrahydrofurandiyl-C1 -C2 loweralkanediyl; wherein the tetrahydrofuran ring is substituted by 0-2 hydroxy groups; Y is a bond; and W is benzimidazol-1-yl or benzimidazol-2-yl are described. These compounds have antiviral activity, antiinflammatory activity and are PAF inhibitors.